Skip to main content

Table 2 Cost-effectiveness results of probabilistic sensitivity analysis

From: Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines

Healthcare system perspective
 Trastuzumab-CT regimenCT only regimenDifference
Total Lifetime Cost (PHP)4,462,4074,010,279452,128
Total LYs gained11.079.871.20
Total QALYs gained8.997.991.00
ICER (PHP per LY gained)377,009
ICER (PHP per QALY gained)453,505